Kong YCM, Wei WZ, Tomer Y. Opportunistic autoimmune disorders: From immunotherapy to immune dysregulation. Ann N Y Acad Sci. 2010;1183:222–36.
Article
CAS
PubMed
Google Scholar
Haanen JBAG, van Thienen H, Blank CU. Toxicity Patterns With Immunomodulating Antibodies and Their Combinations. Semin Oncol. 2015;42:423–8.
Article
CAS
PubMed
Google Scholar
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Topalian SL, Hodi FS, Brahmer JR, Gettinger S, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New Engl J Med. 2012;366:2443–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kong YCM, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front Immunol. 2014;5(May):1–8.
CAS
Google Scholar
Nivolumab (Opdivo®). Prescribing Information. Princeton: Bristol-Meyers Squibb Company; 2015.
Google Scholar
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–65.
Article
CAS
PubMed
Google Scholar
Weber J. Ipilimumab: Controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009;58:823–30.
Article
CAS
PubMed
Google Scholar
Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello SM. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist. 2012;17:525–35.
Article
PubMed
PubMed Central
Google Scholar
Gaudy C, Clévy C, Monestier S, Dubois N, Préau Y, Mallet S, Richard M-A, Grob J-J, Valéro R, Béliard S. Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes. Diabetes Care. 2015;38(November):e182–3.
Article
PubMed
Google Scholar
Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38:e55–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med. 2012;366:2455–65.
Article
CAS
PubMed
PubMed Central
Google Scholar
Okamoto M, Okamoto M, Gotoh K, Masaki T, Ozeki Y, Ando H, Anai M, Sato A, Yoshida Y, Ueda S, Kakuma T, Shibata H. Fulminant Type 1 Diabetes Mellitus with Anti-programmed Cell Death-1 Therapy. J Diabetes Investig. 2016;7:1–4.
Article
Google Scholar
Miyoshi Y, Ogawa O, Oyama Y. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes. Tohoku J Exp Med. 2016;239:155–8.
Article
PubMed
Google Scholar
Martin-liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother. 2015;64:765–7.
Article
PubMed
Google Scholar
Oram RA, Patel K, Hill A, Shields B, McDonald TJ, Jones A, Hattersley AT, Weedon MN. A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care. 2015;39(March):337–44.
PubMed
Google Scholar
Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. Sci Transl Med. 2014;6:230ra45.
Article
PubMed
Google Scholar
Ziegler A-G. Prediction and Pathogenesis in Type 1. Diabetes. 2011;32:206–23.
Google Scholar
Jaberi-Douraki M, Liu SWS, Pietropaolo M, Khadra A. Autoimmune responses in T1DM: quantitative methods to understand onset, progression, and prevention of disease. Pediatr Diabetes. 2014;15:162–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zimmet P, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA. Latent Autoimmune Diabetes Mellitus in Adults (LADA): the Role of Antibodies to Glutamic Acid Decarboxylase in Diagnosis and Prediction of Insulin Dependency. Diabet Med. 1994;11:299–303.
Article
CAS
PubMed
Google Scholar
Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimada A, Shimizu I, Takahashi K, Nagata M, Makino H, Maruyama T. Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig. 2012;3:536–9.
Article
PubMed
PubMed Central
Google Scholar
Imagawa A, Hanafusa T. Pathogenesis of Fulminant Type 1 Diabetes. Rev Diabet Stud. 2006;3:169–77.
Article
PubMed
Google Scholar
Szablewski L. Role of immune system in type 1 diabetes mellitus pathogenesis. Int Immunopharmacol. 2014;22:182–91.
Article
CAS
PubMed
Google Scholar
Leiter E. NOD mice and related strains: origins, husbandry, and biology introduction. In: Leiter E, Atkinson M, editors. NOD Mice and Related Strains: Research Applications in Diabetes, AIDS, Cancer, and Other Diseases. Austin: R. G. Landes Company; 1998. p. 1–26.
Google Scholar
Kochupurakkal NM, Kruger AJ, Tripathi S, Zhu B, Adams LT, Rainbow DB, Rossini A, Greiner DL, Sayegh MH, Wicker LS, Guleria I. Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS One. 2014;9:e89561.
Article
PubMed
PubMed Central
Google Scholar
Ansari MJI, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ, Auchincloss H, Sayegh MH. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003;198:63–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Waterhouse P, Penninger JM, Timms E, Wakeham A. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(80-):985.
Article
CAS
PubMed
Google Scholar
Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone J. Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor- induced stop signal. Nat Immunol. 2009;10:1185.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tsutsumi Y, Jie X, Ihara K, Nomura A, Kanemitsu S, Takada H, Hara T. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes. Diabet Med. 2006;23:1145–50.
Article
CAS
PubMed
Google Scholar
Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–82.
Article
CAS
PubMed
Google Scholar
Wang J, Liu L, Ma J, Sun F, Zhao Z, Gu M. Common variants on cytotoxic T lymphocyte antigen-4 polymorphisms contributes to type 1 diabetes susceptibility: Evidence based on 58 studies. PLoS One. 2014;9:1–9.
Google Scholar
Momin S, Flores S, Angel BB, Codner DE, Carrasco PE, Perez-Bravo F. Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes. Diabetes Res Clin Pract. 2009;83:289–94.
Article
CAS
PubMed
Google Scholar
Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens. 2003;62:492–7.
Article
CAS
PubMed
Google Scholar
El Wafai RJ, Chmaisse HN, Makki RF, Fakhoury H. Association of HLA Class II Alleles and CTLA-4 Polymorphism with Type 1 Diabetes. Saudi J Kidney Dis Transplant. 2011;22:273–81.
Google Scholar
Klitz W, Bugawan TL, Panelo A, Solfelix CM, Buzzetti R, Pozzilli P, Steiner L, Alejandrino M, Erlich HA. Association of CTLA-4 variation with type I diabetes in Filipinos. Immunogenetics. 2002;54:310–3.
Article
CAS
PubMed
Google Scholar
Noble JA, Valdes AM. Genetics of the HLA Region in the Prediction of Type 1 Diabetes. Curr Diab Rep. 2011;11:533–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190–209.
Article
CAS
PubMed
Google Scholar
Erlich H, Valdes AM, Noble J, Carlson J, Varney M, Concannon P, Mychaleckyj JC, Todd J, Bonella P, Fear AL, Lavant E, Louey A, Moonsamy P, Consortium T 1 DG. HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk. Diabetes. 2008;57:1084–92.
Article
CAS
PubMed
PubMed Central
Google Scholar
Valdes AM, Thomson G, Graham J, Zarghami M, McNeney B, Kockum I, Smith A, Lathrop M, Steenkiste AR, Dorman JS, Noble JA, Hansen JA, Pugliese A, Lernmark A, Swedish Childhood Study Group, Diabetes Incidence in Sweden Study Group, Type 1 Diabetes Component of the 13th International Histocompatibility Working Group. D6S265*15 marks a DRB1*15, DQB1*0602 haplotype associated with attenuated protection from type 1 diabetes mellitus. Diabetologia. 2005;48:2540–3.
Article
CAS
PubMed
Google Scholar
Wolchok JD, Kluger H, Callahan MK, Postow M, Rizvi N, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K, Burke MM, Caldwell A, Kronenberg S, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.
Article
CAS
PubMed
Google Scholar